U.S. Markets open in 4 hrs 39 mins
  • S&P Futures

    4,384.75
    -27.00 (-0.61%)
     
  • Dow Futures

    34,900.00
    -74.00 (-0.21%)
     
  • Nasdaq Futures

    14,872.50
    -165.25 (-1.10%)
     
  • Russell 2000 Futures

    2,231.00
    -6.50 (-0.29%)
     
  • Crude Oil

    73.47
    -0.15 (-0.20%)
     
  • Gold

    1,833.40
    -2.40 (-0.13%)
     
  • Silver

    25.67
    -0.11 (-0.43%)
     
  • EUR/USD

    1.1902
    +0.0006 (+0.0476%)
     
  • 10-Yr Bond

    1.2690
    0.0000 (0.00%)
     
  • Vix

    18.90
    +0.59 (+3.22%)
     
  • GBP/USD

    1.3966
    +0.0008 (+0.0545%)
     
  • USD/JPY

    109.5180
    +0.0570 (+0.0521%)
     
  • BTC-USD

    38,943.63
    -1,054.47 (-2.64%)
     
  • CMC Crypto 200

    926.88
    -3.48 (-0.37%)
     
  • FTSE 100

    7,035.52
    -42.90 (-0.61%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Imagine Holding Corcept Therapeutics (NASDAQ:CORT) Shares While The Price Zoomed 398% Higher

·3 min read

We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well, when investors win, they can win big. For example, the Corcept Therapeutics Incorporated (NASDAQ:CORT) share price is up a whopping 398% in the last half decade, a handsome return for long term holders. This just goes to show the value creation that some businesses can achieve.

Check out our latest analysis for Corcept Therapeutics

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

During the last half decade, Corcept Therapeutics became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains.

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

earnings-per-share-growth
earnings-per-share-growth

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. Dive deeper into the earnings by checking this interactive graph of Corcept Therapeutics' earnings, revenue and cash flow.

A Different Perspective

It's nice to see that Corcept Therapeutics shareholders have received a total shareholder return of 110% over the last year. That gain is better than the annual TSR over five years, which is 38%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. It's always interesting to track share price performance over the longer term. But to understand Corcept Therapeutics better, we need to consider many other factors. To that end, you should be aware of the 3 warning signs we've spotted with Corcept Therapeutics .

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.